May 6, 2026- QuidelOrtho Corporation announced financial results for the first quarter ended March 29, 2026.
Key First Quarter 2026 Results:
(all comparisons are to the prior year period)
- Total revenue was $620 million, as reported
- Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.
- Labs revenue of $353 million declined by 5% as reported and 8% in constant currency, primarily due to slower distributor sales in China that the Company believes is related to pending changes to the China National Health Security Administration (“NHSA”) In Vitro Diagnostics (“IVD”) pricing guidelines, business disruption related to the Middle East conflict, and a decrease in revenue related in part to the Company’s termination of its joint business arrangement with Grifols.
- Immunohematology revenue of $138 million grew 8% as reported and 3% in constant currency, primarily driven by growth in North America, China and JPAC.
- GAAP net loss was $92 million; GAAP operating loss was $32 million; adjusted EBITDA was $109 million.
- GAAP diluted loss per share was $1.35; adjusted diluted loss per share was $0.04.